Acetarsol
| Names | |
|---|---|
| Preferred IUPAC name
(3-Acetamido-4-hydroxyphenyl)arsonic acid | |
| Other names
Acetarsone
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.002.349 |
| EC Number |
|
| KEGG | |
| MeSH | Acetarsol |
PubChem CID
|
|
| UNII | |
| UN number | 3465 |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C8H10AsNO5 | |
| Molar mass | 275.0903 g mol−1 |
| Pharmacology | |
| A07AX02 (WHO) G01AB01 (WHO), P01CD02 (WHO), P51AD05 (WHO) | |
| Hazards | |
| GHS labelling: | |
| Danger | |
| H301, H331, H410 | |
| P261, P273, P301+P310, P311, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Acetarsol (or acetarsone, also known as spirocid) is an anti-infective drug. It was first discovered in 1921 at Pasteur Institute by Ernest Fourneau, and sold under the brand name Stovarsol. It was available in oral form and also as a suppository. It has been cancelled and withdrawn from the market since August 12, 1997.
Acetarsol can be used to make arsthinol.